MET signaling has been found to be deregulated in a variety of cancers through different mechanisms, such as overexpression of HGF or MET protein and activating point mutations in the TK domain or affecting the splicing site donor and acceptor regions near exon 14 of the MET gene (so-called “exon 14 skipping mutations”). This evidence concerns the gene MET and cancer.